BIOMARIN PHARMACEUTICAL INC

For the period ended Dec 31, 2023. Filed Feb 26, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 26, 2024

BMRN$57.18+2.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

(In thousands of U.S. Dollars, except per share amounts)

	2023	2022	2021
REVENUES:
Net product revenues	$2,372,538	$2,042,025	$1,783,498
Royalty and other revenues	46,688	54,014	62,777
Total revenues	2,419,226	2,096,039	1,846,275
OPERATING EXPENSES:
Cost of sales	514,854	483,669	470,515
Research and development	746,773	649,606	628,793
Selling, general and administrative	937,291	854,009	759,375
Intangible asset amortization and contingent consideration	62,211	67,193	69,933
Gain on sale of nonfinancial assets, net	—	(108,000)	—
Total operating expenses	2,261,129	1,946,477	1,928,616
INCOME (LOSS) FROM OPERATIONS	158,097	149,562	(82,341)
Interest income	58,339	18,034	10,482
Interest expense	(17,335)	(15,970)	(15,337)
Other income (expense), net	(10,538)	(2,050)	11,846
INCOME (LOSS) BEFORE INCOME TAXES	188,563	149,576	(75,350)
Provision for (benefit from) income taxes	20,918	8,015	(11,270)
NET INCOME (LOSS)	$167,645	$141,561	$(64,080)
EARNINGS (LOSS) PER SHARE, BASIC	$0.89	$0.76	$(0.35)
EARNINGS (LOSS) PER SHARE, DILUTED	$0.87	$0.75	$(0.35)
Weighted average common shares outstanding, basic	187,834	185,266	182,852
Weighted average common shares outstanding, diluted	191,595	188,963	182,852

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.